Variation within the CYP2C19 gene has been linked to differential metabolism of selective serotonin reuptake inhibitors (SSRIs). There is a clear effect of CYP2C19 variation on SSRI metabolism. For example, a recent analysis on 1200 participants identified higher concentrations of sertraline in poor and intermediate metabolisers and slightly lower concentrations in ultrarapid compared to normal metabolisers. Overall, we found evidence for an association between slower CYP2C19 metabolism and adverse side effects. We also observed the expected direction of effects between metaboliser status and treatment response, although efficacy differences were small and often not statistically significant.

Among 5843 depression patients, the association of CYP2C19 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference.[2] Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033).[2] After stratifying by antidepressants primarily metabolized by CYP2C19, no association was found between metabolic phenotypes and antidepressant response, and in conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response.[2] The authors note that reduced metabolism (poor metabolizers) increases drug exposure, whereas rapid and ultrarapid metabolism may reduce exposure and "may lead to treatment failure through a lack of efficacy."[2]

In conclusion, using imputed genotype data, our meta-analysis showed **no significant association between CYP2C19 metabolic phenotypes with antidepressant response**.[1] Moderate evidence of an association with **CYP2C19 poor metabolizers was indicated, which had higher rates of antidepressant remission**.[1] We found CYP2C19 PMs had a higher remission rate compared to CYP2C19 NMs in all samples (OR = 1.46; 95% CI [1.03, 2.06]), which reached nominal significance but was not significant at the multiple testing threshold.[1] CYP2C19 PMs also had a higher remission rate in antidepressants primarily metabolized by CYP2C19…but differences were not significant.[1]

The CPIC guideline for serotonin reuptake inhibitor antidepressants states that CYP2C19 genotype alters metabolism and exposure of several SSRIs. It notes that for citalopram and escitalopram, CYP2C19 poor metabolizers have higher plasma concentrations, which "may increase the probability of side effects," and recommends considering a lower starting dose, slower titration, and 50% reduction of the standard maintenance dose compared with normal metabolizers.[3] For CYP2C19 rapid and ultrarapid metabolizers, lower plasma concentrations "decrease the probability of clinical benefit" and CPIC advises considering a higher maintenance dose or switching to an antidepressant not predominantly metabolized by CYP2C19 if patients do not adequately respond to usual doses.[2]

The earlier CPIC SSRI guideline explains that CYP2C19 ultrarapid metabolizers have significantly lower exposure to citalopram, escitalopram and sertraline than extensive metabolizers and therefore "may have an increased probability of failing therapy." It recommends considering an alternative SSRI not extensively metabolized by CYP2C19 if citalopram or escitalopram are used and efficacy is inadequate at standard maintenance doses.[1] For CYP2C19 poor metabolizers, the guideline notes that they have elevated plasma concentrations of (es)citalopram, and for citalopram the FDA recommends a 50% dose reduction (maximum 20 mg/day) in CYP2C19 poor metabolizers due to QT prolongation risk.[1]

The supplemental material to the CPIC SSRI guideline summarizes pharmacokinetic data showing that genotypic CYP2C19 poor metabolizers carrying *2 or *3 alleles had increased exposure to (es)citalopram by 95% compared with extensive metabolizers, while intermediate metabolizers had 25–30% increased exposure.[5] It notes that CYP2C19 poor metabolizers had significantly higher racemic citalopram or escitalopram plasma concentrations at steady state, which is linked to increased risk of adverse effects and informs the recommendation for dose reduction or alternative therapy in these patients.[5]

CYP2C19 is a **fundamental enzyme in the metabolism of antidepressants**, whose genetic variability is **associated with treatment resistance**, and advocates for the implementation of pharmacogenetic testing to personalize therapy (Zhiganova and Radkova, 2025).[2] CYP2C19 is crucial in the metabolism of commonly used antidepressants in clinical practice, such as **sertraline and escitalopram**.[2] Li et al. (2024) revealed that **CYP2C19 poor metabolizers exhibited a higher remission rate compared to normal metabolizers** (OR = 1.46; 95% CI = 1.03–2.06; p = 0.033), suggesting that **reduced metabolic capacity might lead to higher systemic exposure to active drug forms, thereby enhancing antidepressant efficacy**.[2] Although Li et al. (2024) reported no genome-wide significant correlations between metabolic phenotype and antidepressant response, their findings highlight key pharmacogenetic mechanisms linking CYP polymorphisms to drug pharmacodynamics via altered pharmacokinetics.[2]

Several studies have shown that **poor metabolizers of CYP2D6 or CYP2C19 have higher serum levels of antidepressants and antipsychotics**, compared to normal metabolizers.[4] CYP2D6 and CYP2C19 enzymes are essential in the metabolism of antidepressants and antipsychotics.[4] Genetic variation in these genes results in an **altered enzyme activity and thus may explain some of the interindividual differences in treatment response**.[4] The Clinical Pharmacogenomics Implementation Consortium (CPIC) has developed evidence-based clinical guidelines for SSRIs and tricyclic antidepressants, recommending **adjusted dosing based on CYP2D6 and CYP2C19 metabolic status**.[4]

A ClinPGx annotation of the CPIC guideline for citalopram and escitalopram reiterates that for CYP2C19 poor metabolizers, "higher plasma concentrations may increase the probability of side effects" and recommends considering an antidepressant not predominantly metabolized by CYP2C19, or if citalopram or escitalopram are used, a lower starting dose, slower titration and 50% reduction of the standard maintenance dose.[10] It also cites the FDA warning that for citalopram, 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers because of the risk of QT prolongation.[10]

This study investigated CYP2C19 poor metabolizer phenotype in treatment-seeking patients with bipolar disorder (BP) and major depressive disorder (MDD).[3][5] There was a higher rate of CYP2C19 poor metabolizer phenotype in BP (9.3%) vs. MDD patients (1.7%, p = 0.003); among those with an S-allele, the rate of CYP2C19 PM phenotype was even higher in BP (9.8%) vs. MDD (0.6%, p = 0.003).[3][5] The authors conclude: "There may be underlying pharmacogenomic differences in treatment seeking depressed patients that potentially have impact on serum levels of CYP2C19 metabolized antidepressants (i.e., citalopram / escitalopram) contributing to rates of efficacy vs. side effect burden with additional potential risk of antidepressant response vs. induced mania," and note that PK and PD genetic variation "may contribute to BP and MDD treatment-resistance."[3][5]

The study showed clinically relevant **alterations in exposure of escitalopram and sertraline in relation to the patient´s CYP2C19 genotype**.[5] Certain patients carry **CYP2C19 or CYP2D6 loss-of-function alleles which causes slower metabolism and subsequent elevation in drug exposure**, which can lead to increased incidence or severity of adverse drug reactions or lack of response.[5] Such gene-associated alterations in exposure can lead to the increase of incidence or severity of **adverse drug reactions or lack of response**.[5] Knowledge of the patient’s genotype can individualize the drug treatment resulting in better therapeutic effects.[5]

Because **citalopram, escitalopram, and sertraline are extensively metabolized by CYP2C19**, variants impacting CYP2C19 activity may alter drug exposure.[9] CYP2C19 ultrarapid metabolizers (UMs) and rapid metabolizers (RMs) are predicted to have **lower plasma concentrations** of these SSRIs and may have an **increased risk of therapeutic failure** at standard doses.[9] CYP2C19 poor metabolizers (PMs) have **higher plasma concentrations** and may have increased risk of adverse effects, and **dose reduction or alternative therapy is recommended** depending on the drug.[9]

Variations in the CYP2C19 gene are associated with differential metabolic activity, and thus differential SSRI exposure; accordingly, the metaboliser phenotype can impact SSRI-related drug levels and possibly treatment outcomes. Our results suggest that slower CYP2C19 metabolizers (poor and intermediate) have higher SSRI exposure and are at increased risk of side effects, whereas ultrarapid metabolizers may have lower exposure. However, associations with treatment efficacy were weak, and poor metabolizers in some cohorts showed slightly higher self-reported antidepressant efficacy rather than treatment resistance.

Several antidepressant drugs are metabolized by the CYP2C19 enzyme, including citalopram, escitalopram, sertraline, and amitriptyline.[4] In a large study of the impact of CYP2C19 metabolic phenotypes on antidepressant treatment of bipolar depression, slower CYP2C19 metabolism was associated with a higher risk of treatment-emergent mania, but "there were, however, no clear associations with early treatment persistence, treatment discontinuation, and switching to a new antidepressant."[4] The authors state that although higher plasma concentration of sertraline has been reported in poor CYP2C19 metabolizers, "there is scant evidence to suggest that CYP2C19 metabolic phenotypes affect treatment outcomes or adverse events" and overall their results "show little impact" of CYP2C19 phenotypes on antidepressant treatment continuation in bipolar disorder.[4] They reference prior work suggesting that the CYP2C19 poor metabolism phenotype is more prevalent in treatment-resistant bipolar disorder compared with treatment-resistant major depressive disorder.[4]

We tested if symptom improvement, response and side effects were associated with CYP2C19 metabolic status adjusting for potential confounders. In this naturalistic study of medications for depression, metabolizing status of CYP2C19 showed the expected relationships with antidepressant serum levels and some side effects. However, we found no robust association between CYP2C19 metaboliser status and clinical response or symptom improvement, suggesting that CYP2C19-related differences in metabolism do not consistently translate into treatment-resistant depression.

This genome-wide association study meta-analysis notes that CYP2C19 polymorphisms may provide helpful information for guiding citalopram/escitalopram treatment, despite poor metabolizers being relatively rare among Caucasians (~2%).[7] The paper links to other work showing that elevated CYP2C19 expression (i.e., higher activity) is associated with depressive symptoms and hippocampal homeostasis impairment, highlighting the complex relationship between CYP2C19 activity and depression phenotypes.[7]

CYP2C19*17 is a **gain-of-function allele** associated with ultrarapid drug metabolism.[6] Conclusion: **CYP2C19*17 is likely to cause therapeutic failures in drug treatment with, for example, proton pump inhibitors and antidepressants**.[6] Predictions revealed that CYP2C19*17 homozygotes would attain 35% to 40% lower omeprazole area under the plasma concentration-time curve values than subjects homozygous for CYP2C19*1 taking standard doses of omeprazole.[6]

Individuals who are **CYP2C19 poor metabolizers have a reduced rate of metabolism of amitriptyline compared with normal metabolizers**.[3] As a result, standard doses of amitriptyline lead to **higher plasma levels of amitriptyline, lower levels of nortriptyline, and may increase the risk of side effects**.[3] The effectiveness and tolerability of tricyclics are, therefore, affected by CYP2D6 metabolism and **partially by CYP2C19 metabolism**.[3] It should be noted that a systematic review failed to find consistent replication of association between specific genes (including CYP2D6, CYP2C19, ABCB1, and BDNF among others) and antidepressant response or tolerability in children and young adults, possibly attributable to the lack of power in the reviewed studies.[3]

The SSRIs and SNRIs are all metabolized by cytochrome P450 (CYP) enzymes in the liver, particularly CYP2D6, CYP2C19, and CYP2C9. We observed a low correlation between phenotypes and self-reported adverse outcomes among CYP2D6 and CYP2C19 poor metabolizers identified in our cohort. With respect to CYP2C19 and citalopram/escitalopram, a recent meta-analysis of over 4,000 patients by Fabbri et al. (2018) reported that compared to normal metabolizers, CYP2C19 PMs had a higher risk of gastrointestinal, neurological, and sexual side effects. However, CYP2C19 PMs had significantly increased rates of remission as well as marked improvement in symptoms of depression when compared with normal metabolizers.

Individuals who are CYP2D6 or CYP2C19 "poor metabolizers" (PM) have 2 no function alleles for CYP2D6 or CYP2C19. The FDA-approved drug label for amitriptyline states that PMs will have higher than expected plasma concentrations of amitriptyline at standard doses, increasing the risk of adverse events. Dose reduction or use of alternative therapies may be warranted in patients known to be CYP2C19 PMs when prescribing tricyclic antidepressants such as amitriptyline.

In the 2023 CPIC serotonin reuptake inhibitor guideline, the authors emphasize that altered CYP2C19 activity changes SSRI exposure and can affect both efficacy and tolerability. For citalopram and escitalopram, they recommend that in CYP2C19 rapid or ultrarapid metabolizers, if patients do not adequately respond to usual maintenance dosing, clinicians should consider dose increases or switching to an antidepressant not predominantly metabolized by CYP2C19 because lower exposure decreases the probability of clinical benefit.[2][3] For CYP2C19 poor metabolizers, they advise lower doses and consideration of alternative drugs due to higher concentrations and side-effect risk, which can lead to discontinuation of treatment.[3]

CYP2C19 polymorphisms play a key role in the metabolism of several antidepressants, including **citalopram, escitalopram, sertraline, and tricyclic antidepressants**.[8] These findings suggest that **CYP2C19 polymorphisms may influence the metabolism of some antidepressants but not others**, highlighting the need to consider both genetic background and specific drug characteristics in treatment decisions.[8] Certain loss-of-function alleles result in **poor metabolizer phenotypes with reduced enzyme activity**, while gain-of-function alleles (e.g., CYP2C19*17) confer ultrarapid metabolism and may contribute to **subtherapeutic drug exposure and reduced antidepressant efficacy**.[8]

Most antidepressants are metabolized via CYP enzymes. CYP variants may potentially influence the metabolism of major antidepressants: amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, fluoxetine, paroxetine, sertraline, citalopram, venlafaxine, duloxetine. Among Caucasians, approximately one-quarter of the population is deficient in the enzymatic activity of the CYP2D6–CYP2C19–CYP2C9 cluster responsible for the metabolism of over 60% of current drugs. Citalopram is a major substrate of ABCC1, COMT, CYP2C19 and CYP3A4/5, and a minor substrate of CYP2D6, illustrating that CYP2C19 plays an important role in its metabolism.

The Contemporary Pediatrics review on prescribing SSRIs in youth explains CPIC-based considerations for CYP2C19 genotypes. It states that for CYP2C19 ultrarapid metabolizers, "higher doses of escitalopram or citalopram will only produce low plasma levels and possible lack of efficacy, with a similar but lesser effect for sertraline," indicating risk of nonresponse without dose adjustment.[4] For CYP2C19 poor metabolizers, it notes that usual doses of sertraline may induce an excess of adverse effects and that poor metabolizers treated with escitalopram had more adverse effects, more frequent discontinuation, and different response trajectories compared with normal metabolizers in a cited clinical study.[4]

This clinical pharmacogenetics article explains that both citalopram and escitalopram are metabolized by the CYP2C19 enzyme, and that up to 25% of people in North America carry the *17 allele leading to faster clearance and potential lack of efficacy, so CPIC guidelines recommend alternative medications not metabolized by CYP2C19 for such patients.[6] In contrast, "patients with significantly decreased CYP2C19 function have a much higher risk of side effects when treated at usual doses of citalopram and escitalopram" and "may benefit from a lower starting dose of these medications or a change to an antidepressant that is not metabolized by CYP2C19."[6] The article states that for patients suffering from antidepressant side effects or who present with treatment-resistant depression or anxiety, pharmacogenetic testing "can provide useful insights into a patient’s drug metabolism."[6]

The ClinPGx summary of the CPIC guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and antidepressants describes that this guideline provides dosing recommendations for several SSRIs based on CYP2C19 genotype, including citalopram, escitalopram and sertraline.[6] It notes that the guideline aims to assist clinicians in using genotype results to inform SSRI prescribing, implying that genotype-predicted metabolizer status can influence treatment success and the need for dose adjustments or alternative medications when response is inadequate or side effects occur.[6]

This study examined genetic variability of CYP2D6, CYP2C19, and CYP1A2 in patients with psychotic disorders and depression, specifically focusing on those with treatment resistance to antipsychotics and/or antidepressants.[8] The results reported that patients with treatment resistance demonstrated increased allele frequency of certain CYP variants (including CYP2D6*3 and others), suggesting that pharmacokinetic genetic differences may contribute to inadequate response or side effects under standard dosing of psychotropic medications.[8]

The CPIC guideline for CYP2D6 and CYP2C19 with tricyclic antidepressants, while focused on a different class, reinforces the general pharmacogenetic principle that decreased CYP2C19 activity leads to higher tricyclic plasma concentrations, increasing side-effect risk, whereas increased activity can reduce concentrations and compromise efficacy.[8] This broader CPIC framework supports the concept that CYP2C19 loss-of-function and gain-of-function variants can contribute to variable antidepressant response and the need for dosing changes or alternative drugs when treatment response is suboptimal.[8]

This is the PubMed record for the Frontiers in Pharmacology article on CYP2C19 poor metabolizer phenotype in treatment-resistant depression.[5] It reiterates that there were significantly more CYP2C19 poor metabolizer phenotypes in bipolar disorder (9.3%) versus major depressive disorder patients (1.7%, p = 0.003), and among participants with an S-allele, the rate of CYP2C19 PM phenotype was even higher in bipolar disorder (9.8%) versus MDD (0.6%, p = 0.003).[5] The conclusion emphasizes possible pharmacogenomic differences impacting serum levels of CYP2C19-metabolized antidepressants and notes that evidence for using pharmacogenomics-guided therapy in MDD and BP is "still developing" with a needed focus on drug safety, side-effect burden, and treatment adherence.[5]

An annotation of the CPIC duloxetine guideline indicates that there are currently no recommendations for duloxetine dosing based on CYP2D6 genotypes, and by extension, duloxetine is not a focus of CYP2C19-based dosing guidance.[9] This suggests that the clinical concern about CYP2C19 variants affecting treatment outcomes is concentrated on antidepressants that are substantially metabolized by CYP2C19, such as citalopram, escitalopram and sertraline, rather than all antidepressants.[9]

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline, as cited in this article, recommends that individuals on citalopram or escitalopram with a CYP2C19 poor metabolizer phenotype should reduce the dose by 50% and/or use an alternative antidepressant, because poor metabolizer status is associated with high blood levels and increased risk of side effects.[3] The study notes that the clinical implications of CYP2C19 and serotonin transporter genetic variation are not fully understood, but that PK and PD genetic variation "may contribute" to bipolar and major depressive disorder treatment resistance, and that poor metabolizer phenotype is linked to high drug levels and side-effect burden.[3]

CYP2C19 is your liver’s second major pathway for processing antidepressants. It handles citalopram, escitalopram, sertraline, fluoxetine, and many others. Like CYP2D6, it comes in variants that slow, speed, or eliminate the enzyme’s activity. When CYP2C19 is slow or absent, SSRIs and SNRIs accumulate in your bloodstream. A poor metabolizer can develop toxic levels at doses another person tolerates easily, leading to tremor, nausea, cognitive dulling, sexual side effects, or serotonin syndrome in severe cases. Ultra-rapid metabolizers may clear the drug so quickly that standard doses never reach therapeutic blood levels and they feel no benefit.

Pharmacogenetic studies and implementation projects show that **genetic variation in CYP2C19 and CYP2D6 explains part of the inter-individual variability in antidepressant response and side effects**, but effect sizes are modest and not all studies replicate associations.[2][3][7] Clinical guidelines (e.g., CPIC) recommend **dose adjustments or alternative drugs for CYP2C19 poor and ultrarapid metabolizers** of several SSRIs and tricyclic antidepressants, reflecting concern for both **adverse effects at high exposure** and **therapeutic failure at low exposure** rather than a simple link to treatment resistance.[9] Evidence specifically linking reduced CYP2C19 activity to "relatively treatment-resistant depression" is indirect, focusing instead on altered pharmacokinetics and variable clinical response.[1][2]